What does Avidicure do?
Avidicure is a biotechnology company pioneering a multifunctional antibody modality with broad applicability in oncology. The company is developing dual agonistic, multifunctional, and avidity engineered antibodies known as AVC-Boosters that safely deliver targeted cancer monotherapy by harnessing both the innate and adaptive immune systems.
How much did they raise?
The company raised $50 million in Seed financing, led by EQT Life Sciences with participation from Kurma Partners, BioGeneration Ventures, BOM, Curie Capital, and V-Bio Ventures.
What are their plans for the money?
Avidicure plans to use the funds to further develop its AVC-Booster platform, potentially enhancing cancer treatment options and expanding its product pipeline across multiple oncology indications.
What have they achieved so far?
Avidicure has already made progress with its lead product, AVC-S-101, which is being developed for non-small cell lung cancer and other indications, leveraging its proprietary antibody engineering and in silico protein design capabilities.
